WO2001024625A1 - Transgenic rodent comprising a polynucleotide emcoding a human ucp3 polynucleotide - Google Patents
Transgenic rodent comprising a polynucleotide emcoding a human ucp3 polynucleotide Download PDFInfo
- Publication number
- WO2001024625A1 WO2001024625A1 PCT/GB2000/003747 GB0003747W WO0124625A1 WO 2001024625 A1 WO2001024625 A1 WO 2001024625A1 GB 0003747 W GB0003747 W GB 0003747W WO 0124625 A1 WO0124625 A1 WO 0124625A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- polynucleotide
- polypeptide
- sequence
- seq
- rodent
- Prior art date
Links
- 108091033319 polynucleotide Proteins 0.000 title claims description 72
- 102000040430 polynucleotide Human genes 0.000 title claims description 72
- 239000002157 polynucleotide Substances 0.000 title claims description 72
- 241000283984 Rodentia Species 0.000 title claims description 35
- 230000009261 transgenic effect Effects 0.000 title claims description 34
- 102000008200 Uncoupling Protein 3 Human genes 0.000 claims abstract description 19
- 108010021098 Uncoupling Protein 3 Proteins 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 17
- 108700019146 Transgenes Proteins 0.000 claims description 51
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 49
- 229920001184 polypeptide Polymers 0.000 claims description 48
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 48
- 108090000623 proteins and genes Proteins 0.000 claims description 31
- 230000014509 gene expression Effects 0.000 claims description 23
- 230000001105 regulatory effect Effects 0.000 claims description 20
- 210000002027 skeletal muscle Anatomy 0.000 claims description 16
- 239000013598 vector Substances 0.000 claims description 16
- 101000747597 Homo sapiens Mitochondrial uncoupling protein 3 Proteins 0.000 claims description 15
- 102000053554 human UCP3 Human genes 0.000 claims description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 14
- 230000000694 effects Effects 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 9
- 201000010099 disease Diseases 0.000 claims description 9
- 108091026890 Coding region Proteins 0.000 claims description 7
- 230000037396 body weight Effects 0.000 claims description 7
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000029663 wound healing Effects 0.000 claims description 6
- 102000007469 Actins Human genes 0.000 claims description 5
- 108010085238 Actins Proteins 0.000 claims description 5
- 208000008589 Obesity Diseases 0.000 claims description 5
- 208000035475 disorder Diseases 0.000 claims description 5
- 235000013601 eggs Nutrition 0.000 claims description 5
- 238000002347 injection Methods 0.000 claims description 5
- 239000007924 injection Substances 0.000 claims description 5
- 235000020824 obesity Nutrition 0.000 claims description 5
- 206010061218 Inflammation Diseases 0.000 claims description 4
- 230000004054 inflammatory process Effects 0.000 claims description 4
- 201000001320 Atherosclerosis Diseases 0.000 claims description 3
- 206010006895 Cachexia Diseases 0.000 claims description 3
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 3
- 231100000272 reduced body weight Toxicity 0.000 claims description 3
- 230000017423 tissue regeneration Effects 0.000 claims description 3
- 238000004520 electroporation Methods 0.000 claims description 2
- 238000001638 lipofection Methods 0.000 claims description 2
- 230000001177 retroviral effect Effects 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 210000004291 uterus Anatomy 0.000 claims description 2
- 230000001747 exhibiting effect Effects 0.000 claims 2
- 101710112412 Mitochondrial uncoupling protein 3 Proteins 0.000 claims 1
- 102100040216 Mitochondrial uncoupling protein 3 Human genes 0.000 claims 1
- 210000003205 muscle Anatomy 0.000 claims 1
- 238000011830 transgenic mouse model Methods 0.000 abstract description 7
- 238000002360 preparation method Methods 0.000 abstract description 2
- 230000004075 alteration Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 230000006870 function Effects 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 11
- 102000015494 Mitochondrial Uncoupling Proteins Human genes 0.000 description 10
- 108010050258 Mitochondrial Uncoupling Proteins Proteins 0.000 description 10
- 108010021111 Uncoupling Protein 2 Proteins 0.000 description 10
- 102000008219 Uncoupling Protein 2 Human genes 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 210000001519 tissue Anatomy 0.000 description 10
- 108020004414 DNA Proteins 0.000 description 9
- 108020004705 Codon Proteins 0.000 description 8
- 101000939438 Homo sapiens Mitochondrial brown fat uncoupling protein 1 Proteins 0.000 description 8
- 241000699660 Mus musculus Species 0.000 description 8
- 241000699670 Mus sp. Species 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 7
- 239000008103 glucose Substances 0.000 description 7
- 102100029820 Mitochondrial brown fat uncoupling protein 1 Human genes 0.000 description 6
- 239000002299 complementary DNA Substances 0.000 description 6
- 238000003780 insertion Methods 0.000 description 6
- 230000037431 insertion Effects 0.000 description 6
- 230000002018 overexpression Effects 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 4
- 238000012217 deletion Methods 0.000 description 4
- 230000037430 deletion Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 235000012631 food intake Nutrition 0.000 description 4
- 239000012634 fragment Substances 0.000 description 4
- 238000010363 gene targeting Methods 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000006467 substitution reaction Methods 0.000 description 4
- 241000282412 Homo Species 0.000 description 3
- 210000003486 adipose tissue brown Anatomy 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 238000003198 gene knock in Methods 0.000 description 3
- 238000003209 gene knockout Methods 0.000 description 3
- 108020004999 messenger RNA Proteins 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 238000012552 review Methods 0.000 description 3
- 230000002123 temporal effect Effects 0.000 description 3
- 230000035924 thermogenesis Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 206010008531 Chills Diseases 0.000 description 2
- 102000018251 Hypoxanthine Phosphoribosyltransferase Human genes 0.000 description 2
- 108010091358 Hypoxanthine Phosphoribosyltransferase Proteins 0.000 description 2
- 108091092195 Intron Proteins 0.000 description 2
- 108010002747 Pfu DNA polymerase Proteins 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 108010091086 Recombinases Proteins 0.000 description 2
- 102000018120 Recombinases Human genes 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 108010052160 Site-specific recombinase Proteins 0.000 description 2
- 238000002105 Southern blotting Methods 0.000 description 2
- 108091081024 Start codon Proteins 0.000 description 2
- XJLXINKUBYWONI-DQQFMEOOSA-N [[(2r,3r,4r,5r)-5-(6-aminopurin-9-yl)-3-hydroxy-4-phosphonooxyoxolan-2-yl]methoxy-hydroxyphosphoryl] [(2s,3r,4s,5s)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl phosphate Chemical compound NC(=O)C1=CC=C[N+]([C@@H]2[C@H]([C@@H](O)[C@H](COP([O-])(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](OP(O)(O)=O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 XJLXINKUBYWONI-DQQFMEOOSA-N 0.000 description 2
- 239000000556 agonist Substances 0.000 description 2
- 239000005557 antagonist Substances 0.000 description 2
- 230000003542 behavioural effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000004590 computer program Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 210000004602 germ cell Anatomy 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 230000010354 integration Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000002438 mitochondrial effect Effects 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 238000007410 oral glucose tolerance test Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- NCYCYZXNIZJOKI-IOUUIBBYSA-N 11-cis-retinal Chemical compound O=C/C=C(\C)/C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-IOUUIBBYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 210000002237 B-cell of pancreatic islet Anatomy 0.000 description 1
- 102000004657 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Human genes 0.000 description 1
- 108010003721 Calcium-Calmodulin-Dependent Protein Kinase Type 2 Proteins 0.000 description 1
- 235000005881 Calendula officinalis Nutrition 0.000 description 1
- 240000001432 Calendula officinalis Species 0.000 description 1
- 108700010070 Codon Usage Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 108010046276 FLP recombinase Proteins 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 101000747587 Homo sapiens Mitochondrial uncoupling protein 2 Proteins 0.000 description 1
- 101100048292 Homo sapiens UCP3 gene Proteins 0.000 description 1
- 208000023105 Huntington disease Diseases 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- 102000011782 Keratins Human genes 0.000 description 1
- 108010076876 Keratins Proteins 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102100040420 Mitochondrial thiamine pyrophosphate carrier Human genes 0.000 description 1
- 101710112402 Mitochondrial uncoupling protein 1 Proteins 0.000 description 1
- 208000026072 Motor neurone disease Diseases 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 108010021466 Mutant Proteins Proteins 0.000 description 1
- 102000008300 Mutant Proteins Human genes 0.000 description 1
- 102000004364 Myogenin Human genes 0.000 description 1
- 108010056785 Myogenin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000364051 Pima Species 0.000 description 1
- 102000004330 Rhodopsin Human genes 0.000 description 1
- 108090000820 Rhodopsin Proteins 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 210000000593 adipose tissue white Anatomy 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000036760 body temperature Effects 0.000 description 1
- 230000006583 body weight regulation Effects 0.000 description 1
- GEHJBWKLJVFKPS-UHFFFAOYSA-N bromochloroacetic acid Chemical compound OC(=O)C(Cl)Br GEHJBWKLJVFKPS-UHFFFAOYSA-N 0.000 description 1
- 210000001593 brown adipocyte Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 238000012411 cloning technique Methods 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000009547 development abnormality Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000034525 diet induced thermogenesis Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 210000001671 embryonic stem cell Anatomy 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000001976 enzyme digestion Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 231100000221 frame shift mutation induction Toxicity 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 239000000446 fuel Substances 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 230000014101 glucose homeostasis Effects 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000003284 homeostatic effect Effects 0.000 description 1
- 102000053575 human UCP2 Human genes 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003999 initiator Substances 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 210000001700 mitochondrial membrane Anatomy 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 208000005264 motor neuron disease Diseases 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 210000001719 neurosecretory cell Anatomy 0.000 description 1
- 229930027945 nicotinamide-adenine dinucleotide Natural products 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 108020001580 protein domains Proteins 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000002741 site-directed mutagenesis Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
- A01K67/027—New or modified breeds of vertebrates
- A01K67/0275—Genetically modified vertebrates, e.g. transgenic
- A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2207/00—Modified animals
- A01K2207/15—Humanized animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2217/00—Genetically modified animals
- A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2227/00—Animals characterised by species
- A01K2227/10—Mammal
- A01K2227/105—Murine
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
Definitions
- the present invention relates to a transgenic animal expressing the human uncoupling protein 3 (UCP3) gene and to the uses thereof. Furthermore the invention relates to methods for constructing the transgenic animal and to the transgenes used in this construction.
- UCP3 human uncoupling protein 3
- mice Mus musculus
- the mouse genome can be manipulated in several ways:
- transgene either randomly (pronuclear injection) or into pre-determined locus (via ES cells).
- transgenic mice expressing transgenes represent gain-of-function mutations. Loss-of- fiinction mutations are usually obtained by gene targeting. However, overexpression of a dominant negative mutant protein may result in the functional knockout of the gene of interest (e.g. Stacey et al., Nature 332, 131, 1988). Most commonly, transgenesis is used for the study of tissue- and developmental stage-specific gene regulation, for experiments of the phenotypic effects of transgene expression or for the creation of mouse models of human disease, in particular neurodegenerative conditions like Alzheimer's disease, Huntington's disease, motor neuron disease etc (for general review see R. Jaenisch, Science 240, 1468, 1988).
- the transgenic construct is microinjected into the male pronucleus of fertilised eggs (Gordon and Ruddle, Science 214, 1244, 1981), resulting in the random integration into one locus of a varying number of copies, usually in a head to tail array (Costantini and Lacy, Nature 294, 92, 1981):
- transgenes can be introduced via ES cells, using electroporation, retroviral vectors or lipofection for gene transfer. This has been successfully demonstrated for a number of very large, BAC or YAC derived transgenes (Hodgson et al., Neuron 23, 181, 1999; Lamb et al., Nature Neuroscience 2, 695, 1999).
- transgenes can be inserted into pre-determined loci (ROSA26, HPRT etc.) that support transcriptional activity and whose disruption by the insertional mutagenesis is without consequences (Zambrowicz et al., Proc Natl Acad Sci USA 94, 3789, 1997; P. Soriano, Nature Genetics 21, 70, 1999). Again, this technology is ES cell based and essentially a special case of gene knock-in (see below). Transgenes can also be expressed in other rodents, for example rats (e.g.
- transgene is introduced into the animal by pronuclear injection as the ES cell route is currently only available for mice.
- Gene knockout involves the conversion of the gene of interest into a null allele, thus completely disrupting the function of the gene (Joyner AL (editor) Gene targeting: A practical approach. IRL Press, Oxford, England, 1993). Analysis of the resulting phenotype may then allow conclusions as to the function of the gene product.
- This technology is based on the homologous recombination in embryonic stem cells of a suitable targeting vector with the endogenous gene.
- a positive-negative selection strategy is used to enrich for ES cell clones that have undergone the desired recombination event (Thomas and Capecchi, Cell 51, 503, 1987; Soriano et al., Cell 64, 693, 1991).
- Gene knock-in is based on the same principle of homologous recombination as gene knockout. However, a gene knock- in is not designed to ablate the function of the gene but to introduce changes in the coding (or in some instances intron) sequence that are intended to alter the function of the endogenous gene. This may range from a single nucleotide exchange (point mutation; e.g. Cho et al., Science 279, 867, 1998) to the deletion (or addition) of sequences that encode functional protein domains (e.g.
- Mitochondrial uncoupling proteins are inner mitochondrial membrane proteins whose function is to uncouple mitochondrial respiration from ADP phosphorylation (see Ricquier et al (1999) J Intern Med 245(6):637-42 for review).
- the first member of the family, mitochondrial uncoupling protein 1 (UCP1; Bouillaud et al (1985) Proc Natl Acad Sci 82(2) p445-448; Jacobsson et al (1985) J. Biol. Chem. 260(30) pi 6250- 16254), is expressed exclusively in the brown adipocyte.
- the second member of the uncoupling protein family uncoupling protein-2,
- UCP2 was reported independently by Fleury et al. (Nature Genetics 15, 269, 1997) and Gimeno, et al. (Diabetes 46, 900-906, 1997). UCP2 shares 59% identity to UCP1 at the amino acid level. However, unlike UCP1, UCP2 is more widely expressed in human tissues predominantly in white adipose tissue, skeletal muscle (a major site of fuel utilisation and thermogenesis) and components of the immune system The varying level of expression of UCP2 in mouse strains with differential susceptibility to weight gain is consistent with it playing some role in weight gain potential (Fleury et al. 1997 supra). In mice, UCP2 maps close to a quantitative trait locus (QTL) on chromosome 7 associated with obesity.
- QTL quantitative trait locus
- UCP3 Shortly after the publication of the sequence for UCP2 a third member of the uncoupling protein family was identified and termed UCP3 (W098/39432 (SmithKline Beecham); Boss et al., FEBS left 408 39-42, 1997; Vidal-Puig et al., Biochem.Biophys.Res.Commun. 235 79-82, 1997).
- UCP3 is 73% identical to UCP2 and 59% identical to UCP1 at the amino acid level. In contrast to the wide tissue distribution of UCP2, UCP3 mRNA is predominantly expressed in skeletal muscle.
- Skeletal muscle is an important site for resting metabolic rate and UCP3 levels in skeletal muscle may be a determinant of energy expenditure and metabolic efficiency in Pima Indians (Schrauwen et al., Diabetes 48 146-149, 1999).
- UCP3 also maps to 1 lql3 and is adjacent to UCP2 to within 100 kb (Gong et al., Biochem.Biophys.Res.Commun. 256 27-32, 1997; Solanes et al., 1997 supra) suggesting that they are evolutionarily very close.
- UCP3 has also been implicated in wound healing (SmithKline Beecham pic patent application WO00/02577).
- the present invention provides a transgenic rodent having a genome comprising a polynucleotide encoding a human UCP3 polypeptide under the control of a regulatory sequence facilitating expression of said polypeptide.
- polynucleotides include:
- a polynucleotide comprising a polynucleotide sequence having at least 95%, 96%, 97%, 98%>, or 99% identity to the polynucleotide sequence of SEQ ID NO: 1 ;
- polynucleotide comprising the polynucleotide of SEQ ID NO: 1 ;
- polynucleotide comprising a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO-.2;
- polynucleotide having a polynucleotide sequence encoding a polypeptide sequence having at least 95%, 96%, 97%, 98%, or 99% identity to the polypeptide sequence of SEQ ID NO:2;
- the transgenic rodent is a mouse or rat, preferably a mouse.
- transgenic construct follows standard cloning techniques, that are well known in the art (for example see Sambrook et al., Molecular Cloning: A
- the cDNA to be overexpressed can be prepared from a mRNA extracted from a relevant tissue, preferably a tissue in which the protein of interest is known to be expressed for example skeletal muscle.
- the cDNA, along with the promoter of choice and other components such as artificial introns and reporter genes, can then be inserted into a cloning vector by restriction digest and ligation. Suitable cloning vectors for the assembly of transgenes provide for acceptable yields of DNA.
- Vectors such as pBluescript are particularly preferred as in addition to good yield, they provide desirable unique restriction sites flanking the transgene (for example BssHII in pBluescript) for convenient removal of the vector portion of the construct prior to pronucleus injection. Should any of the components of the transgene inserted into the vector contain within their sequence additional restriction sites that are identical to the flanking restriction sites, such restiction sites will clearly not be unique and so alternative restriction sites must be identified or introduced for effective vector removal without transgene disruption.
- the transgene can be isolated from genomic DNA.
- the expression of the transgene in the host genome may be controlled temporally and/ or spatially by placing the transgene under the control of an appropriate regulatory sequence, for example a promoter.
- an appropriate regulatory sequence for example a promoter.
- the choice of promoter depends on the biological question that the mouse model is intended to answer. Most transgenes contain tissue-specific promoters that, in the best case scenario, lead to a spatially and temporally authentic (with respect to the endogenous gene) expression pattern of the transgene. Other promoters provide for ubiquitous expression across the entire organism.
- tissue specific promoters is the alpha-actin promoter that drives transcription in skeletal muscle. There are many other tissue-specific promoters that can be used.
- Such promoters include, but are not limited to, the calcium-calmodulin dependent Kinase II (CamKII) promoter for expression in neurons and neurosecretory cells; albumin promoter for hepatocytes; insulin promoter for pancreatic beta cells; rhodopsin promoter for retinal rods and cones; myogenin promoter for skeletal muscle; promoters of certain keratins for derm is; etc.
- CamKII calcium-calmodulin dependent Kinase II
- Regulatory sequences such as promoters, are operably linked to the coding sequence of the gene of interest in a manner that will permit the required temporal and spatial expression of the transgene.
- Methods of so linking regulatory sequences to cDNAs to facilitate their expression are widely known in the art. Such methods include directly ligating a polynucleotide sequence comprising a regulatory sequence to the coding region of the transgene. Additional polynucleotide sequences may be included that modulate expression in the required manner. Examples of additional sequences include enhancer elements, artificial introns and others.
- nucleotide sequence of a known promoter, or other regulatory sequence may be modified to increase levels of expression. Such modifications can be achieved using, for example, site- directed mutagenesis methods well known in the art (see Sambrook et al, supra).
- the coding sequence of the gene of interest may be modified to enhance or otherwise affect expression levels.
- the codon usage of the transgene can be altered to match more closely that of the host. It is well known in the art that different organisms use the 64 coding and stop codons at different frequencies. Codons that are infrequently used in an organism are termed "rare codons". If a transgene includes a codon that is a rare codon in the host, expression levels may be severely reduced. One solution is to replace one or more rare codons in the transgene with codons that are frequently used in the host. Other modifications to the transgene sequence include modifying the polynucleotide sequence surrounding the start codon (the initiator methionine encoding codon) to make this more closely match the consensus "Kozak" sequence (A/G)
- the vector portions are removed by restriction enzyme digestion, for example by using restriction sites in the vector that flank the transgene.
- the genetic material that is actually introduced into the host cell will preferably comprise the coding sequence of the gene of interest and the regulatory sequences to which it has been operably linked together with other potential components of the transgene, for example a reporter gene. More preferably the genetic material will have only the transgene and the regulatory sequences to which it has been operably linked.
- transgene a genetic material
- the most commonly used protocol comprises direct injection of the transgene into the male pronucleus of the fertilised egg (Hogan et al., Manipulating the mouse embryo (A laboratory manual) Second edition, CSHL Press 1994).
- the injected eggs are then re-transferred into the uteri of pseudo- pregnant recipient mothers.
- Some of the resulting offspring may have one or several copies of the transgene integrated into their genomes, usually in one integration site.
- These "founder" animals are then bred to establish transgenic lines and to back-cross into the genetic background of choice. It is convenient to have the transgene insertion on both chromosomes (homozygosity) as this obviates the need for repeated genotyping in the course of routine mouse husbandry.
- transgenes are genetically modified by the same genetic disorder as a whole plant.
- ES pluripotent embryonic stem
- Transgenes of up to several hundred kilobases of rodentian DNA have been used to produce transgenic mice in this manner (for example Choi et al., Nature Genet. 4, 117-123 (1993); Strauss et al., Science 259, 1904-07 (1993)).
- transgene is inserted into a pre-determined locus (non-random ly, for example ROSA26 or HPRT) that supports ubiquitous as well as tissue specific expression of the transgene (Vivian et al., BioTechniques 27, 154-162 (1999)).
- the transgenic rodent is subsequently tested to ensure the required genotypic change has been effected. This can be done by, for example, detecting the presence of the transgene by PCR with specific primers, or by Southern blotting of tail DNA with a specific probe. Testing for homozygosity of the transgene insertion may be carried out using quantitative Southern blotting to detect a twofold difference in signal strength between hetero- and homozygous transgenic rodents.
- the transgenic rodent line is subjected to various tests to determine the gain-of- function phenotype. The tests involved in this phenotypic characterisation depend on what genotypic change has been effected, and may include, for example, morphological, biochemical and behavioural studies.
- the polynucleotide encoding the UCP3 polypeptide, as defined hereinabove is predominantly expressed in skeletal muscle.
- Such near-exclusive expression may be facilitated by the transcriptional activity of skeletal muscle specific promoters.
- the skeletal muscle- specific promoter is the alpha-actin promoter.
- Phenotypic tests can be devised for examining the effect of overexpressing the human UCP3 gene. Such tests are based on the hypothesis that UCP3 protein uncouples the respiratory chain in the mitochondria from the generation of energy rich molecules (NADP, NADPH, and ultimately ATP, GTP), with the result that there is excess heat production. Thus, simple measurements like weight gain, food intake and body temperature are preferred phenotypic tests for the initial analysis of the UCP3 transgenic rodents. Subsequently, glucose clearance and other parameters of glucose homeostasis can be investigated. In addition the time required for wound healing and general behavioural trends may be investigated. Based on the results of these studies, further more specific tests can be devised to give a more detailed analysis of the consequences of UCP3 expression.
- transgenic rodents of the present invention can also be used to test the efficacy of a drug and a drug administration regime for the treatment of UCP3-related diseases such as obesity, diabetes, hyperlipidaemia, body weight disorders, wound healing, cachexia, inflammation, tissue repair and atherosclerosis
- UCP3-related diseases such as obesity, diabetes, hyperlipidaemia, body weight disorders, wound healing, cachexia, inflammation, tissue repair and atherosclerosis
- the present invention provides a method of determining the phenotypic effect of a compound comprising exposing a transgenic rodent overexpressing human UCP3 as hereinabove described to said compound and determining changes in phenotype.
- transgenic rodents could be used to investigate the effects of various drug treatments on the course of the disease (in the animal model setting).
- transgenic overexpression models may produce surprising, unexpected results by way of the resulting phenotype. This could result in the identification of "new" disease indications, or serve as a warning, for example when the transgenic rodents display developmental abnormalities or develop tumours.
- a "Transgene” comprises a polynucleotide, isolated from nature, which has been manipulated in-vitro and subsequently introduced into the genome of the same or a different species in either the native or modified forms, such that it is stably and heritably maintained in that genome.
- Native forms include unmodified polynucleotides isolated from a source different to that into which it is subsequently introduced, for example a human polynucleotide sequence introduced into a mouse genome.
- Modified polynucleotides include those which have one or more nucleotide substitutions, deletions, insertions or inversions.
- Native or modified polynucleotides may be operably linked to a heterologous promoter, or other regulatory sequence, from a different gene within the same species or from a gene in a different species.
- a polynucleotide is operably linked to a regulatory sequence when, for example, it is placed under the transcriptional control of said regulatory sequence.
- the polynucleotide may or may not encode a polypeptide, and if a polypeptide is expressed from the polynucleotide, said polypeptide may or may not be. full-length relative to that encoded by the original polynucleotide isolated.
- transgene is generally used to refer to the polynucleotide and the regulatory sequences to which it is operably linked.
- transgenic organism An organism into which a transgene has been introduced is termed a "transgenic" organism.
- regulatory sequences refer to DNA or RNA polynucleotide sequences, which are usually non-coding, that are involved in the regulation of transcriptional activity or tissue-specific enhancement or silencing of gene transcription.
- Such regulatory sequences include promoters and enhancers.
- Identity as known in the art, is a relationship between two or more polypeptide sequences or two or more polynucleotide sequences, as determined by comparing the sequences.
- identity also means the degree of sequence relatedness between polypeptide or polynucleotide sequences, as the case may be, as determined by the match between strings of such sequences.
- Identity and similarity can be readily calculated by known methods, including but not limited to those described in (Computational Molecular Biology, Lesk, A.M., ed., Oxford University Press, New York, 1988; Biocomputing: Informatics and Genome Projects, Smith, D. W., ed., Academic Press,
- Preferred computer program methods to determine identity and similarity between two sequences include, but are not limited to, the GCG program package (Devereux, J., et al., Nucleic Acids Research 12(1): 387 (1984)), BLASTP, BLASTN, and FASTA (Atschul, S.F. et al., J. Molec. Biol. 215: 403-410 (1990).
- the BLAST X program is publicly available from NCBI and other sources (BLAST Manual, Altschul, S., et al, NCBI NLM NIH Bethesda, MD 20894; Altschul, S., et al, J. Mol. Biol. 215: 403-410 (1990).
- the well known Smith Waterman algorithm may also be used to determine identity.
- Preferred parameters for polypeptide sequence comparison include the following:
- a polynucleotide sequence of the present invention may be identical to the reference sequence of SEQ ID NO: l, that is be 100% identical, or it may include up to a certain integer number of nucleotide alterations as compared to the reference sequence.
- Such alterations are selected from the group consisting of at least one nucleotide deletion, substitution, including transition and transversion, or insertion, and wherein said alterations may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, interspersed either individually among the nucleotides in the reference sequence or in one or more contiguous groups within the reference sequence.
- the number of nucleotide alterations is determined by multiplying the total number of nucleotides in SEQ ID NO: 1 by the numerical percent of the respective percent identity(divided by 100) and subtracting that product from said total number of nucleotides in SEQ ID NO: l, or: ⁇ *n - (*n • y)» wherein n n is the number of nucleotide alterations, x n is the total number of nucleotides in SEQ ID NO: 1 , and y is, for instance, 0.70 for 70%, 0.80 for 80%, 0.85 for 85%, 0.90 for 90%, 0.95 for 95%,etc, and wherein any non-integer product of x n and y is rounded down to the nearest integer prior to subtracting it from x n .
- Alterations of a polynucleotide sequence encoding the polypeptide of SEQ ID NO:2 may create nonsense, missense or frameshift mutations in this coding sequence and thereby alter the polypeptide encoded by the polynucleotide following such alterations.
- a polypeptide sequence of the present invention may be identical to the reference sequence of SEQ ID NO:2, that is be 100% identical, or it may include up to a certain integer number of amino acid alterations as compared to the reference sequence such that the % identity is less than 100%.
- Such alterations are selected from the group consisting of at least one amino acid deletion, substitution, including conservative and non-conservative substitution, or insertion, and wherein said alterations may occur at the amino- or carboxy-terminal positions of the reference polypeptide sequence or anywhere between those terminal positions, interspersed either individually among the amino acids in the reference sequence or in one or more contiguous groups within the reference sequence.
- the number of amino acid alterations for a given % identity is determined by multiplying the total number of amino acids in SEQ ID NO:2 by the numerical percent of the respective percent identity(divided by 100) and then subtracting that product from said total number of amino acids in SEQ ID NO:2, or: na ⁇ X a " ( x a * y)» wherein n a is the number of amino acid alterations, x a is the total number of amino acids in SEQ ID NO:2, and y is, for instance 0.70 for 70%, 0.80 for 80%, 0.85 for 85% etc., and wherein any non- integer product of x a and y is rounded down to the nearest integer prior to subtracting it from x a .
- Human UCP3 cDNA was amplified by PCR using Pfu polymerase (Stratagene), from a cDNA comprising the polynucleotide sequence of SEQ ID NO: 1 as template, using techniques well known in the art.
- the PCR product was sequenced and cloned into the EcoRV site of pBluescript (Stratagene) via blunt end ligation.
- the human skeletal muscle specific alpha-actin promoter was excised from vector pACTSV40 (Fazeli et al (1996) J Cell Biol, 135 p241-251) as a 2.2 kb Hindlll fragment, and cloned into the unique Smal site of the vector from 1.1, again via blunt end ligation.
- the arificial intron-SV40 polyA cassette was excised from the vector of 1.3 as a Sall- Xhol fragment and cloned into the Xhol site of the vector of 1.2 downstream of the human UCP3 cDNA.
- transgene DNA was excised from the vector of 1.4 with Kpnl and partial Notl restriction enzyme digests, gel-purified as a 3.9 kb DNA fragment, and injected into male pronuclei of fertilised eggs.
- Example 2 Phenotypic effect of human UCP3 overexpression in transgenic mice
- Male and female mice expressing human skeletal muscle UCP3 and age-matched wild-type C57Bl/6xCBA mice were housed in threes on a 12 h light cycle. Measurements of body weight and food consumption were commenced at 4 weeks until 12 weeks of age. All mice were fed TEK 2018 (TEKLAD) diet. Oral glucose tolerance tests were performed at 8 and 12 weeks of age. Tail-tip blood was measured at times 0 and then 45, 90 and 135 min following an oral glucose (3 g/kg) load. Plasma glucose concentrations were determined and glucose disposal depicted as area under the glucose response curve with time.
- Figure 2 shows the effect of overexpression of human UCP3 in mouse skeletal muscle on glucose disposal. Glucose disposal deduced from the area under the OGTT curve was greater in humanUCP3 transgenic mice compared to wild type mice. Data from 10 - 12 animals per group, *P ⁇ 0.05.
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Environmental Sciences (AREA)
- Veterinary Medicine (AREA)
- Biodiversity & Conservation Biology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- Animal Husbandry (AREA)
- General Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001527639A JP2003510097A (en) | 1999-10-01 | 2000-09-29 | Transgenic rodent comprising a polynucleotide encoding a human UCP3 polynucleotide |
AU75384/00A AU7538400A (en) | 1999-10-01 | 2000-09-29 | Transgenic rodent comprising a polynucleotide emcoding a human ucp3 polynucleotide |
EP00964449A EP1263284A1 (en) | 1999-10-01 | 2000-09-29 | Transgenic rodent comprising a polynucleotide encoding a human ucp3 polypeptide |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB9923334.8A GB9923334D0 (en) | 1999-10-01 | 1999-10-01 | Novel transgenic animal |
GB9923334.8 | 1999-10-01 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001024625A1 true WO2001024625A1 (en) | 2001-04-12 |
Family
ID=10862009
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB2000/003747 WO2001024625A1 (en) | 1999-10-01 | 2000-09-29 | Transgenic rodent comprising a polynucleotide emcoding a human ucp3 polynucleotide |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1263284A1 (en) |
JP (1) | JP2003510097A (en) |
AU (1) | AU7538400A (en) |
GB (1) | GB9923334D0 (en) |
WO (1) | WO2001024625A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001043760A2 (en) * | 1999-12-17 | 2001-06-21 | Smithkline Beecham P.L.C. | Use of ucp3 polynucleotides and polypeptides |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998045438A1 (en) * | 1997-04-09 | 1998-10-15 | Beth Israel Deaconess Medical Center | Ucp3: an uncoupling protein homologue |
WO1999010013A1 (en) * | 1997-08-25 | 1999-03-04 | The Trustees Of The University Of Pennsylvania | The use of insulin-like growth factor-i in muscle |
-
1999
- 1999-10-01 GB GBGB9923334.8A patent/GB9923334D0/en not_active Ceased
-
2000
- 2000-09-29 JP JP2001527639A patent/JP2003510097A/en active Pending
- 2000-09-29 WO PCT/GB2000/003747 patent/WO2001024625A1/en not_active Application Discontinuation
- 2000-09-29 AU AU75384/00A patent/AU7538400A/en not_active Abandoned
- 2000-09-29 EP EP00964449A patent/EP1263284A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998045438A1 (en) * | 1997-04-09 | 1998-10-15 | Beth Israel Deaconess Medical Center | Ucp3: an uncoupling protein homologue |
WO1999010013A1 (en) * | 1997-08-25 | 1999-03-04 | The Trustees Of The University Of Pennsylvania | The use of insulin-like growth factor-i in muscle |
Non-Patent Citations (2)
Title |
---|
BOSS O. ET AL.: "THE UNCOUPLING PROTEINS, A REVIEW", EUROPEAN JOURNAL OF ENDOCRINOLOGY, vol. 139, no. 1, 1998, pages 1 - 9, XP000916888, ISSN: 0804-4643 * |
STEFL B. ET AL.: "Brown fat is essential for cold-induced thermogenesis but not for obesity resistance in aP2-Ucp mice.", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 274, no. 3 PART 1, March 1998 (1998-03-01), pages E527 - E533, XP002161151, ISSN: 0002-9513 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001043760A2 (en) * | 1999-12-17 | 2001-06-21 | Smithkline Beecham P.L.C. | Use of ucp3 polynucleotides and polypeptides |
WO2001043760A3 (en) * | 1999-12-17 | 2001-12-27 | Smithkline Beecham Plc | Use of ucp3 polynucleotides and polypeptides |
Also Published As
Publication number | Publication date |
---|---|
AU7538400A (en) | 2001-05-10 |
GB9923334D0 (en) | 1999-12-08 |
JP2003510097A (en) | 2003-03-18 |
EP1263284A1 (en) | 2002-12-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Valet et al. | Understanding adipose tissue development from transgenic animal models | |
CN105518132B (en) | LincRNA-deficient non-human animals | |
Chaible et al. | Genetically modified animals for use in research and biotechnology | |
Moller | Transgenic approaches to the pathogenesis of NIDDM | |
Sung et al. | Functional genomics approach using mice | |
Zollner et al. | Animal models of T cell-mediated skin diseases | |
Vivian et al. | Temporal, spatial and tissue-specific expression of a myogenin-lacZ transgene targeted to the Hprt locus in mice | |
JP4811765B2 (en) | An expression vector that can control the inducible expression of foreign genes | |
JP5481661B2 (en) | Mutation gene production method | |
WO2001024625A1 (en) | Transgenic rodent comprising a polynucleotide emcoding a human ucp3 polynucleotide | |
WO2009142724A2 (en) | Novel gpr101 transgenic mice and methods of use thereof | |
Noakes | Creation of transgenic mice | |
Treuting et al. | Generation of genetically altered mouse models for aging studies | |
US20120227118A1 (en) | Mo-1 conditional knock-out non-human animal and uses thereof | |
Li et al. | The caveats and setbacks of mouse genome editing tools in biomedical studies | |
EP1319709A1 (en) | Disruption of the glutathione S-transferase-omega-1 gene | |
Andersen | Genetically engineered mice and their use in aging research | |
Liu et al. | Transgenesis | |
USH2056H1 (en) | Model for von Hippel-Lindau disease | |
Pasparakis | Making gene-modified mice | |
JP2006524049A (en) | Animals and cells containing mutant α2 / δ1 genes | |
Wang et al. | Transgenesis and genome editing in chickens | |
US20090077680A1 (en) | Genetically Engineered and Photyped Mice and Stem Cell Clones for Producing the Same | |
Mayford et al. | Conditional and inducible gene targeting in the nervous system | |
Dumbell et al. | Genetically Altered Mice as an Approach for the Investigation of Obesity and Metabolic Disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 527639 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000964449 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: 2000964449 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2000964449 Country of ref document: EP |